Therapeutic Solutions International Inc (TSOI)

[centsability4me]

More on MemoryMune :

http://therapeuticsolutionsint.com/?page_id=74

The patent describes methods, protocols and compositions of matter useful for stimulation of anticancer immune responses. In one embodiment of the invention, culturing of buffy coat cells is performed in an environment resembling non-physiological conditions. Buffy coat derived products are subsequently harvested, concentrated, and added to a culture of monocytes and lymphocytes. Conditioned media from this second culture is subsequently utilized as an injectable solution for stimulation of anticancer immunity.

MemoryMune therefore is a product derived from a two-step culture process of donor blood cells. MemoryMune is being developed with the purpose of reawakening dormant immune memory cells by mimicking a process called “homeostatic immune expansion”. It is known that many cancer patients possess memory T cells that enter the tumor, however, once inside the tumor these cells are inactivated. MemoryMune contains a unique combination of growth factors specific for immune system cells called “cytokines”.

“There are numerous ways of activating the immune system to kill cancer. Although in many cases therapies show some level of efficacy, in the majority of situations tumors come back, in part because of inability of the immune system to form and maintain proper memory T cells,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “Based on our early data, it appears that MemoryMune may be capable of overcoming memory cell exhaustion, thus providing cancer patients a fighting chance of inhibiting tumor recurrence.”

“In contrast to conventional T cells, memory T cells have a reduced need for ‘co-stimulation’, meaning that they are primed and ready to induce immune response against cancer cells when cancer re-occurs. Unfortunately in cancer patients, ‘blocking factors’ are generated by tumors which inhibit function of memory T cells. The cytokines in MemoryMune, such as interleukin-7 and interleukin-15 have been previously shown to re-activate memory cells. We believe MemoryMune is a means of delivering cytokines such as these in a physiological manner,” said Dr. Thomas Ichim, Director of Therapeutic Solutions International.